David A. Beebe
Pfizer (United States)(US)
Publications by Year
Research Areas
Pancreatic function and diabetes, Peroxisome Proliferator-Activated Receptors, Aldose Reductase and Taurine, Diabetes Treatment and Management, Cannabis and Cannabinoid Research
Most-Cited Works
- → Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage(2000)4,242 cited
- → X-Ray Crystallographic and Kinetic Studies of Human Sorbitol Dehydrogenase(2003)98 cited
- → Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems(2020)89 cited
- → Pyridones as glucokinase activators: Identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle(2009)80 cited
- → A Highly Selective, Non-Hydantoin, Non-Carboxylic Acid Inhibitor of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one(2003)68 cited
- → Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus(2011)68 cited
- → A Novel Series of Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and Congeners(2005)65 cited
- → Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK)(2017)49 cited
- → Orally-Effective, Long-Acting Sorbitol Dehydrogenase Inhibitors: Synthesis, Structure−Activity Relationships, and in Vivo Evaluations of Novel Heterocycle-Substituted Piperazino-Pyrimidines(2001)48 cited
- → Spirolactam-Based Acetyl-CoA Carboxylase Inhibitors: Toward Improved Metabolic Stability of a Chromanone Lead Structure(2013)47 cited